Ozempic and Beyond: The Truth About GLP-1's for Weight Loss and Beyond

Announcement: 'Not Your Mother's Hormones' will be rebranded to 'The Longevity Link' in order to better encapsulate the content being provided this season. We are touching on a broader range of topics that embrace healthspan, lifespan and longevity. Look for the change soon!

In this episode of 'Not Your Mother's Hormones,' Christine Givant explores the incredible potential of GLP1 agonists, a class of drugs that includes popular treatments like Ozempic and Mounjaro (semaglutide and Tirzepatide).

Initially used for diabetes management, these drugs have been shown to support weight loss in a dramatic fashion and explains that they are not side-effect free. Christine goes on to explain evidence that these drugs may also improve cardiovascular health, decrease inflammation and potentially play a role in staving off Alzheimer's Disease. Chris discusses the moral dilemmas surrounding their use, emphasizing the positive potential for individuals to reduce or eliminate the need for multiple prescriptions. Christine also introduces the idea of Microdosing these peptides to treat obesity and many other indications with little to no side-effects. She explains the important role of the compounding pharmacy in delivering unique versions of these medications where warranted. As we eagerly anticipate the show's rebranding to 'The Longevity Link,' this episode sets the stage for upcoming discussion for extending healthspan, lifespan and longevity.